What do systematic reviews say?

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 267 participants
  Very low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 267 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 65 participants
  Low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 65 participants
  Low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 425 participants
  High

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 425 participants
  High

Intervention not reported

The review found no eligible studies for this question.

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 756 participants
  Moderate

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 756 participants
  Moderate

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 327 participants
  Moderate

Selective serotonin reuptake inhibitors vs atypical agent

• Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Low

Selective serotonin reuptake inhibitors vs atypical agent

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with atypical agent (low certainty).

• Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
  RR 0.94 [0.79, 1.11]
  1 study · 70 participants
  Low

Selective serotonin reuptake inhibitors vs atypical agent

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with atypical agent (low certainty).

• Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
  RR 0.78 [0.52, 1.17]
  1 study · 70 participants
  Low

Selective serotonin reuptake inhibitors vs atypical agent

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in study dropouts at 6‐12 weeks compared with atypical agent (low certainty).

• Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
  RR 1.67 [0.43, 6.45]
  1 study · 70 participants
  Low

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

RISPERIDONE DEPOT showed no clear difference in mental state: PANSS responders (ITT data) ‐ medium term PANSS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 1.01 [0.83, 1.23]
  2 studies · 1326 participants
  Moderate

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

RISPERIDONE DEPOT may leads to lower leaving the study early: lack of efficacy ‐ long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 0.6 [0.45, 0.81]
  1 study · 749 participants
  Low

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

RISPERIDONE DEPOT probably leads to higher adverse events: Movement disorder requiring the use of anti‐EPS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 1.46 [1.18, 1.8]
  2 studies · 1666 participants
  Moderate

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 2350 participants
  Low